Psyched Wellness Successfully Completes Writing the Final Extraction Protocol, the Assembly of Safety & Efficacy Narratives, and Writing the Safety Data Sheet (SDS) For Its First Product

Toronto, Ontario, December 10, 2020 – Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTCQB:DCNPF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has successfully completed a comprehensive process of lab experiments which have determined the Company’s final extraction protocol, that will be used for the company’s first line of products.

The company is also pleased to share that it has completed the assembly of the safety and efficacy narratives, and the writing of the safety data sheets (SDS) for its unique Amanita Muscaria extract.

“A number of milestones have been completed that have allowed us to progress to this stage of development,” said Brian Tancowny, Head Chemist at Psyched Wellness. Our optimization of the extraction process allows for greater expansion in the production arena, allowing greater capacity and yield of the psychoactive compound, Muscimol. This novel compound has many pleiotrophic effects that could have potentially wide-ranging health benefits.”

David Shisel, COO of the Company says, “With the completion of the final extraction process and finalizing the SDS, we are now able to start producing larger-scale extraction and ship it abroad. The team is doing a great job and I am confident we will be able to start our pre-clinical trials with our CRO partner in Asia before year ends”.